> Merck has ended its collaboration with BioXell on its sepsis drug TREM-1. BioXell says it will seek another company with which to partner on the drug. Report [1]
> Shire is expanding its U.S. operations, adding 360 jobs in Pennsylvania. Release [2]
> According to a new report, pressure to reduce costs and time-to-market has lead to a rapid growth in the CRO market, which was valued at $14 billion in 2006 and is predicted to balloon to $24 billion by 2010. Release [3]
> Galapagos has gained a milestone payment in its collaboration with Boehringer Ingelheim. Release [4]
And Finally... The biotech and technology industries are at odds over a new bill designed to revamp the patent process. Article [5]
Links:
[1] http://www.fiercebiotech.com/node/7727
[2] http://www.fiercebiotech.com/node/7720
[3] http://www.fiercebiotech.com/node/7721
[4] http://www.fiercebiotech.com/node/7722
[5] http://www.fiercebiotech.com/node/7716